ADAP
Adaptimmune Therapeutics
ADAP
ADAP
68 hedge funds and large institutions have $122M invested in Adaptimmune Therapeutics in 2022 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 20 increasing their positions, 15 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
12% less funds holding
Funds holding: 77 → 68 (-9)
37% less capital invested
Capital invested by funds: $195M → $122M (-$72.6M)
44% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 18
Holders
68
Holding in Top 10
1
Calls
$78K
Puts
$2K
Top Buyers
| 1 | +$410K | |
| 2 | +$272K | |
| 3 | +$227K | |
| 4 |
Morgan Stanley
New York
|
+$201K |
| 5 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$118K |
Top Sellers
| 1 | -$1.1M | |
| 2 | -$706K | |
| 3 | -$503K | |
| 4 |
Rafferty Asset Management
New York
|
-$369K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$229K |